Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:53:02.462Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:53:02.462Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Scribe Therapeutics Inc.
Market Cap
$264.25M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $264.25M | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
